跳至主要内容
临床试验/EUCTR2005-005239-80-GB
EUCTR2005-005239-80-GB
进行中(未招募)
1 期

Prospective study to assess the emergence of drug resistance to oseltamivir following treatment of acute influenza A among children - Oseltamivir resistance study

niversity Hospitals Leicester, Leicester General Hospital0 个研究点目标入组 100 人2005年12月2日
适应症Influenza A
相关药物tamiflu suspension

概览

阶段
1 期
干预措施
未指定
疾病 / 适应症
Influenza A
发起方
niversity Hospitals Leicester, Leicester General Hospital
入组人数
100
状态
进行中(未招募)
最后更新
6年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2005年12月2日
结束日期
2008年10月1日
最后更新
6年前
研究类型
Interventional clinical trial of medicinal product

研究者

发起方
niversity Hospitals Leicester, Leicester General Hospital

入排标准

入选标准

  • Inclusion criteria
  • Boys and girls must satisfy the following to qualify for the study:
  • 1\. Aged between \>1 and 12 years
  • 2\. Parents or legal guardians willing to give written informed consent
  • 3\. Presenting within 48 hours of onset of an acute febrile illness including acute respiratory tract illness, febrile seizure, febrile gastrointestinal illness, acute febrile illness with temp \>38oC
  • 4\. Willing for post treatment sampling to be conducted
  • 5\. Able to adhere with oseltamivir treatment (5 days b.d dosing with paediatric suspension)
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) no

排除标准

  • Exclusion criteria
  • 1\. unable to obtain informed consent
  • 2\. conditions presenting with: rash, known bacterial aetiology, non\-respiratory conditions with known aetiology, allergy to oseltamivir
  • 3\. presence of underlying condition requiring dose alteration of oseltamivir e.g. severe renal failure
  • 4\. Concomitant therapy requiring oseltamivir dose alteration including methotrexate and probenecid
  • 5\. inability to obtain nasopharyngeal sample for analysis
  • 6\. concurrent enrollment in any therapeutic intervention studies

结局指标

主要结局

未指定

相似试验